Trading Signals: AUTL Stock Price Prediction and Forecast (Fri. Jun. 22, 2018 - Fri. May. 13, 2022)(Autolus Therapeutics plc )
| AUTL latest price $3.2500 (4.33%) ($3.2500 - $3.2500) on Mon. May. 2, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.57% (three month average) | RSI | 22 | Latest Price | $3.2500(4.33%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | AUTL declines -1.8% a day on average for past five trading days. | Weekly Trend | AUTL declines -10.8% a week on average for past two weeks. | Market Behavior | Growth stock rally for large cap. Growth stock rally for small cap. | Correlated ETFs | Broad market will support AUTL advance at 0% a week (0% probability) XLC(95%) QQQ(93%) IVE(91%) INDA(89%) XBI(88%) | Factors Impacting AUTL price | AUTL will decline at least -1.785% in a week (0% probabilities). SHY(-47%) IGOV(-26%) USO(-18%) LIT(-18%) SLV(-11%) | | | | | Relative Volatility | | | | Market Trend Strength | -1.785% (StdDev 3.57%) | Hourly BBV | 1.5 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-21.21(-752.62%) | Resistance Level | $3.79 | 5 Day Moving Average | $3.2(1.56%) | 10 Day Moving Average | $3.36(-3.27%) | 20 Day Moving Average | $3.79(-14.25%) | To recent high | -30.6% | To recent low | 4.8% | Market Cap | $170m | | | | Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. |